NCT04900779 is a clinical trial in Major Elective Abdominal and Thoracic Surgery, sponsored by Hospital Universitari Vall d'Hebron Research Institute.

Who is sponsoring NCT04900779?

NCT04900779 is sponsored by Hospital Universitari Vall d'Hebron Research Institute.

What condition does NCT04900779 study?

NCT04900779 studies Major Elective Abdominal and Thoracic Surgery.

Is NCT04900779 still recruiting?

NCT04900779 is currently status unknown. Last updated 25 May 2021.

Last reviewed 2021-05-25 · How we verify

NCT04900779

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Glycocalyx in Major Abdominal and Thoracic Surgery

Status unknown Last updated 25 May 2021

What this trial tests

trial in Major Elective Abdominal and Thoracic Surgery in 117 participants. Status unknown.

Timeline

2 February 2021

Primary endpoint
1 December 2021

31 May 2022

Quick facts

Lead sponsor	Hospital Universitari Vall d'Hebron Research Institute
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	117
Start date	2 February 2021
Primary completion	1 December 2021
Estimated completion	31 May 2022
Sites	1 location across Spain

Conditions studied

Major Elective Abdominal and Thoracic Surgery — all drugs for Major Elective Abdominal and Thoracic Surgery →

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

18 and older, any sex, with Major Elective Abdominal and Thoracic Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: The glycocalyx is a fundamental component of the endothelial barrier and alterations at this level have been shown to exacerbate the inflammatory response in the microcirculation. Its degradation in the surgical patient, has been tested in interventions that involve regional or general ischemia, for example in cardiac surgery, major vascular surgery or transplantation. On interventions that do not involve ischemic events the literature is limited, such is the case of those patients undergoing major abdominal and thoracic surgery. Objective: Assess whether there is a glycocalyx degradation in major elective abdominal and thoracic surgery, measured as an increase in plasma syndecane-1 levels during the first 24 hours of postoperative care. Methodology: Prospective observational study in patients undergoing major elective thoracic and abdominal surgery at the University Hospital Vall d´Hebrón. Measurement of the syndecane-1 plasma levels are going to be done during the first 24 hours after the intervention. It is intended to evaluate whether its elevation is related to anesthetic perioperative factors, and if it has an impact con morbildity and mortality in the following 6 months after the procedure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Early plasma syndecan-1 dynamics and their prognostic value in major thoracic and abdominal surgery: a prospective observational study.
Laurens LM, Alonso M, Perurena J, de Miguel M, et al · · 2026 · PMID 41484899 · DOI 10.1186/s13741-025-00642-5

Verify or expand the search:

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04900779 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
Last refreshed: 25 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04900779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing